Carflzomib: A next-generation proteasome inhibitor for multiple myeloma treatment

Clinical Journal of Oncology Nursing

Volumn 17, Issue 2, 2013, Pages

  Bilotti, Elizabeth ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARFILZOMIB; OLIGOPEPTIDE; PROTEASOME INHIBITOR;

CLINICAL TRIAL (TOPIC); HUMAN; MULTIPLE MYELOMA; NURSING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ARTICLE; SURVIVAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84875669366     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/13.CJON.E35-E44     Document Type: Article

References (45)

1. Alsina, M., Trudel, S., Furman, R.R., Rosen, P.J., O'Connor, O.A., Comenzo, R.L., Goy, A. (2012). A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carflzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clinical Cancer Research, 18, 4830-4840.
2. Badros, A.Z., Vij, R., Martin, T., Zonder, J.A., Kunkel, L., Wang, Z., Niesvizky, R. (2013). Carflzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. Advance online publication. doi:10.1038/leu.2013.29
3. Baird-Powell, S. (2006). Hyponatremia/hypernatremia. In D. Camp-Sorrell & R. Hawkins (Eds.), Clinical manual for the oncology advanced practice nurse (2nd ed., pp. 1049-1057). Pittsburgh, PA: Oncology Nursing Society.
4. Bilotti, E., Gleason, C.L., & McNeill, A. (2011). Routine health maintenance in patients living with multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(Suppl. 1), S25-S40. doi:10.1188/11.S1.CJON.25-40
5. Bisanz, A.K., Woolery, M.J., & Eaton, L.H. (2009). Constipation. In L.H. Eaton & J.M. Tipton (Eds.), Putting evidence into practice: Improving oncology patient outcomes (pp. 85-90). Pittsburgh, PA: Oncology Nursing Society.
6. ClinicalTrials.gov. (2013). Phase 3 study with carfilzomib and dexamethasone versus velcade and dexamethasone for relapsed multiple myeloma patients (ENDEAVOR). Retrieved from http://www.clinicaltrials.gov/ct2/show/NCT01568866?term=NCT015 68866&rank=1
7. Damron, B.I., Samsonow, S.M., & Belansky, H. (2009). Prevention of bleeding. In L.H. Eaton & J.M. Tipton, J.M. (Eds.), Putting Evidence Into Practice: Improving oncology patient outcomes (pp. 253-255). Pittsburgh, PA: Oncology Nursing Society.
8. Demo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Bennett, M.K. (2007). Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 6383-6391.
9. Dimopoulos, M.A., Terpos, E., Chanan-Khan, A., Leung, N., Ludwig, H., Jagannath, S., San Miguel, J. (2010). Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. Journal of Clinical Oncology, 28, 4976-4984. doi:10.1200/JCO.2010.30.8791
10. DiSalvo, W.M., Joyce, M.M., & Belansky, H. (2009). Dyspnea. In L.H. Eaton & J.M. Tipton (Eds.), Putting evidence into practice: Improving oncology patient outcomes (pp. 135-138). Pittsburgh, PA: Oncology Nursing Society.
11. Faiman, B.M., Mangan, P., Spong, J., Tariman, J.D., & The International Myeloma Foundation Nurse Leadership Board. (2011). Renal complications in multiple myeloma and related disorders: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15 (Suppl. 1), S66-S76. doi:10.1188 /11.CJON.S1.66 -76
12. Hájek, R., Bryce, R., Ro, S., Klencke, B., & Ludwig, H. (2012). Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carflzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer, 12, 415. doi:10.1186/1471-2407-12-415
13. Harvey, D., Lonial, S., Patel, P., McCulloch, L., Niesvizky, R., & Kaufman, J. (2012). Carflzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on he-modialysis [Abstract 0844]. Haematologica, 97(Suppl. 2), 346.
14. Jagannath, S., Vij, R., Stewart, A.K., Trudel, S., Jakubowiak, A.J., Reiman, T., Siegel, D.S. (2012). An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carflzomib in patients with relapsed and refractory multiple myeloma. Clinical Lymphoma, Myeloma, and Leukemia, 12, 310-318. doi:10.1016/j.clml.2012.08.003
15. Jakubowiak, A.J., Dytfeld, D., Griffth, K.A., Lebovic, D., Vesole, D.H., Jagannath, S., Vij, R. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120, 180-189. doi:10.1182/blood-2012-04-422683
16. Kennedy, M.M. (2006). Pneumonia. In D. Camp-Sorrell & R. Hawkins (Eds.), Clinical manual for the oncology advanced practice nurse (2nd ed., pp. 195-208). Pittsburgh, PA: Oncology Nursing Society.
17. Kolb, B., Hulin, C., Caillot, D., Benboubker, L., Tiab, M., Blin, N., Moreau, P. (2012). Phase I/II study of carflzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma [Abstract 8009]. Retrieved from http://www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&con fID=114&abstractID=96240
18. Kumar, S.K., Lee, J.H., Lahuerta, J.J., Morgan, G., Richardson, P.G., Crowley, J., Durie, B.G. (2012). Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study. Leukemia, 26, 149-157.
19. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Gertz, M.A. (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
20. Lonial, S., Niesvizky, R., McCulloch, L., Rajangam, K., & Vij, R. (2012). Cardiac and pulmonary safety profile of single-agent carflzomib from four phase 2 studies in patients with relapsed and/or refractory multiple myeloma [Abstract 4037]. Retrieved from http://abstracts.hematologylibrary.org/cgi/content/abstract/ ashmtg;120/21/4037
21. Martin, T., Vij, R., Badros, A., Patel, P., McCulloch, L., & Jagannath, S. (2012). Carflzomib is associated with a low rate of typically mild to moderate, nondose-limiting treatment-emergent peripheral neuropathy [Abstract 0857]. Haematologica, 97(Suppl. 1), 352.
22. Miceli, T., Colson, K., Gavino, M., & Lilleby, K. (2008). Myelosup-pression associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(Suppl. 1), 13-20. doi:10.118 8/ 08.CJON.S1.13 -19
23. Mikhael, J.R., Reeder, C.B., Libby, E.N., III, Costa, L.J., Bergsagel, P.L., Buadi F, Stewart, A.K. (2012). Results from the phase II dose expansion of cyclophosphamide, carflzomib, thalido-mide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma [Abstract 445]. Retrieved from http://abstracts.hematologylibrary.org/cgi/content/abstract/ ashmtg;120/21/445
24. Mitchell, S.A., & Beck, S.L. (2009). Fatigue. In L.H. Eaton & J.M. Tipton (Eds.), Putting evidence into practice: Improving oncology patient outcomes (pp. 149-153). Pittsburgh, PA: Oncology Nursing Society.
25. Moreau, P., Palumbo, A.P., Stewart, A.K., Rajkumar, V., Jakubowiak, A.J., Halka, K., Siegel, D.S. (2011). A randomized, multicenter, phase (Ph) III study comparing carflzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM) [Abstract TPS225]. Retrieved from http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=102&abstract ID=83643
26. Moreau, P., Richardson, P.G., Cavo, M., Orlowski, R.Z., San Miguel, J.F., Palumbo, A., & Harousseau J.L. (2012). Proteasome inhibitors in multiple myeloma: 10 years later. Blood, 120, 947-959. doi:10.1182/blood-2012-05-403733
27. Muehlbauer, P., Thorpe, D., & Belansky, H. (2009). Diarrhea. In L.H. Eaton & J.M. Tipton (Eds.), Putting evidence into practice: Improving oncology patient outcomes (pp. 119-125). Pittsburgh, PA: Oncology Nursing Society.
28. National Cancer Institute Cancer Therapy Evaluation Program. (2010). Common terminology criteria for adverse events [v.4.03]. Retrieved from http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
29. Niesvizky, R., Martin, T.G., 3rd, Bensinger, W., Alsina, M., Siegel, D.S., Kunkel, L.A., Wang, M. (2013). Phase Ib dose-escalation study (PX-171-006) of carflzomib, lenalidomide, and low-dose dexa-methasone in relapsed or progressive multiple myeloma. Clinical Cancer Research. Advance online publication. doi:10.1158/1078 - 0432.CCR-12-3352
30. Nooka, A.K., Badros, A.Z., Patel, P., McCulloch, L., Lonial, S., & Kaufman, J.L. (2012). Hematologic safety data from four phase II studies of single-agent carflzomib in relapsed and/or refractory multiple myeloma [Abstract 8086]. Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_vi ew&confID=114&abstractID=91894
31. O'Connor, O.A., Stewart, A.K., Vallone, M., Molineaux, C.J., Kunkel, L.A., Gerecitano, J.F., & Orlowski, R.Z. (2009). A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carflzomib (PR-171) in patients with hema-tologic malignancies. Clinical Cancer Research, 15, 7085-7091.
32. Onyx Pharmaceuticals Inc. (2012). Kyprolis™ (carflzomib) for injection [Package insert]. San Francisco, CA: Author.
33. Papadopoulos, K., Lee, P., Singhal, S., Holahan, J.R., Tolcher, A.W., Patnaik, A., Siegel, D.S. (2011). PX-171-007: A phase 1b study evaluating the safety and effcacy of a 30-minute IV infusion of carflzomib in patients with relapsed and/or refractory multiple myeloma [Abstract 0898]. Haematologica, 96(Suppl. 2), 374.
34. Richardson, P.G., Delforge, M., Beksac, M., Wen, P., Jongen, J.L., Sezer, O., Sonneveld, P. (2011). Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 26, 595-608. doi:10.1038/leu.2011.346
35. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Benjamin, E.J., Berry, J.D., Borden, W.B., Turner, M.B. (2012). Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation, 125, e2-e220. doi:10.1161/ CIR.0b013e31823ac046
36. Siegel, D.S., Martin, T., Wang, M., Vij, R., Jakubowiak, A.J., Lonial, S., Jagannath, S. (2012). A phase 2 study of single-agent carflzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 120, 2817-2825. doi:10.1182/ blood-2012-05-425934
37. Siegel, D.S., Wang, M., Martin, T.G., Infante, J.R., Kaufman, J.L., Ran-jangam, K., Vij, R. (2012). A phase 2 study of prolonged carfl-zomib therapy in patients with multiple myeloma previously enrolled in carflzomib clinical trials [Abstract 2962]. Retrieved from https://ash.confex.com/ash/2012/webprogram/Paper49064.html
38. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63, 11-30. doi:10.3322/caac.2116 6
39. Smith, L.C., Bertolotti, P., Curran, K., & Jenkins, B. (2008). Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 37-51. doi:10.118 8/08.CJON.S1.37-51
40. Sonneveld, P., Asselbergs, E., Zweegman, S., Van der Holt, B., Kersten, M.J., Vellenga, E., Lokhorst, H. (2012). Carflzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate [Abstract 333]. Retrieved from http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/333
41. Suter, P.M., Gorski, L.A., Hennessey, B., & Suter, W.N. (2012). Best practices for heart failure: A focused review. Home Healthcare Nurse, 30, 394-405. doi:10.1097/NHH.0b013e31825b11ab
42. Tariman, J.D., Love, G., McCullagh, E., & Sandifer, S. (2008). Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 29-35. doi:10.1188/08.CJON.S1.29-35
43. Tyson, L. (2006). Dyspnea. In D. Camp-Sorrell & R. Hawkins (Eds.), Clinical manual for the oncology advanced practice nurse (2nd ed., pp. 153-157). Pittsburgh, PA: Oncology Nursing Society.
44. Vij, R., Siegel, D.S., Jagannath, S., Jakubowiak, A.J., Stewart, A.K., Mc-Donagh, K., Wang, M. (2012). An open-label, single-arm, phase 2 study of single-agent carflzomib in patients with relapsed and/ or refractory multiple myeloma who have been previously treated with bortezomib. British Journal of Haematology, 158, 739-748.
45. Vij, R., Wang, M., Kaufman, J.L., Lonial, S., Jakubowiak, A.J., Stewart, A.K., Siegel, D.S. (2012). An open-label, single-arm, phase II (PX-171-004) study of single-agent carflzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood, 119, 5661-5670. doi:10.1182/blood-2012-03-414359